The Pan-Immune-Inflammation Value in Patients with Metastatic Melanoma Receiving First-Line TherapyGiovanni Fucà, Michele Del Vecchio, Giovanni Randon et al.|Targeted Oncology|2021Cited by 61
Everolimus plus aromatase inhibitors as maintenance therapy after first-line chemotherapy: Final results of the phase III randomised MAIN-A (MAINtenance Afinitor) trialValentina Guarneri, PierFranco Conte, Carlo Alberto Giorgi et al.|European Journal of Cancer|2021Cited by 13
Immune-related Bell’s palsy in melanoma patients treated with immune checkpoint inhibitorsTeresa Beninato, Carolina Cimminiello, Giovanni Fucà et al.|Melanoma Research|2021Cited by 5